N/A
N=62
Study of the Effect of the Drug Gabapentin on Postoperative Pain and Incidence of Postoperative Nausea and Vomiting
Obesity, Morbid · Postoperative Pain · Postoperative Nausea and Vomiting
Bottom Line
View on ClinicalTrials.gov: NCT00886236 ↗Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Sep 2018
Primary outcome: Primary: Evaluate the Amount of Diluadid Given Postoperatively — 11.035; 8.7; 12.4 ml
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Gabapentin (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medical University of South Carolina
- Primary completion
- Jan 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Evaluate the Amount of Diluadid Given Postoperatively |
11.035; 8.7; 12.4 | — |
| PRIMARY Number of Participants Who Experience Incidence of Postoperative Nausea. |
12; 11; 12 | — |
| SECONDARY Evaluate Incidence of Respiratory Depression as Evidenced by Pulse Oximetry Data |
93; 94; 95 | — |
Summary
The purpose of this research study is to evaluate the drug gabapentin (Neurontin®) for its ability to reduce postoperative pain, the need for morphine-like pain medication, and the severity and frequency of postoperative nausea and vomiting in laparoscopic gastric bypass surgery patients.
Eligibility Criteria
Inclusion Criteria
- Patients undergoing laparoscopic gastric bypass surgery
- Age > 18 years
Exclusion Criteria
- Patients under the age of 18 years
- Patients who undergo open gastric bypass
- Patients with a history of chronic pain treated with pregabalin, gabapentin or opioids
- Patients with a history of chronic renal disease (creatinine > 1.3)
- Patients with a history of bleeding gastric ulcer
Data sourced from ClinicalTrials.gov (NCT00886236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.